28.00
price up icon8.78%   2.26
after-market After Hours: 28.29 0.29 +1.04%
loading
Denali Therapeutics Inc stock is traded at $28.00, with a volume of 867.08K. It is up +8.78% in the last 24 hours and up +3.40% over the past month. Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$25.74
Open:
$25.59
24h Volume:
867.08K
Relative Volume:
0.94
Market Cap:
$4.01B
Revenue:
$340.81M
Net Income/Loss:
$-145.22M
P/E Ratio:
-25.69
EPS:
-1.09
Net Cash Flow:
$-370.93M
1W Performance:
-2.20%
1M Performance:
+3.40%
6M Performance:
+46.06%
1Y Performance:
+30.35%
1-Day Range:
Value
$25.59
$28.07
1-Week Range:
Value
$25.28
$28.07
52-Week Range:
Value
$14.56
$32.13

Denali Therapeutics Inc Stock (DNLI) Company Profile

Name
Name
Denali Therapeutics Inc
Name
Phone
(650) 866-8548
Name
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Name
Employee
364
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
DNLI's Discussions on Twitter

Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-13-23 Initiated Citigroup Buy
Nov-20-23 Resumed JP Morgan Overweight
Oct-24-23 Resumed Cantor Fitzgerald Overweight
Sep-06-23 Initiated B. Riley Securities Buy
Jan-30-23 Initiated SVB Securities Outperform
Dec-05-22 Initiated Cowen Outperform
Nov-02-22 Upgrade BTIG Research Neutral → Buy
Nov-02-22 Initiated BofA Securities Buy
Jun-23-22 Initiated Berenberg Buy
Dec-10-21 Resumed Raymond James Mkt Perform
Sep-21-21 Initiated Oppenheimer Outperform
Sep-01-21 Initiated SMBC Nikko Outperform
May-18-21 Initiated UBS Buy
Feb-26-21 Reiterated H.C. Wainwright Buy
Feb-10-21 Upgrade Cantor Fitzgerald Neutral → Overweight
Nov-11-20 Reiterated H.C. Wainwright Buy
Oct-16-20 Downgrade BTIG Research Buy → Neutral
Sep-14-20 Resumed JP Morgan Overweight
Aug-20-20 Reiterated H.C. Wainwright Buy
Mar-13-20 Upgrade Evercore ISI In-line → Outperform
Feb-28-20 Upgrade Wedbush Neutral → Outperform
Feb-24-20 Initiated Jefferies Buy
Feb-19-20 Initiated Stifel Hold
Jan-27-20 Upgrade Goldman Neutral → Buy
Sep-26-19 Initiated Wedbush Neutral
Sep-13-19 Initiated Nomura Buy
Aug-09-19 Initiated BTIG Research Buy
Jun-26-19 Initiated H.C. Wainwright Buy
Nov-15-18 Initiated Cantor Fitzgerald Overweight
Nov-12-18 Initiated Janney Buy
Mar-12-18 Downgrade Evercore ISI Outperform → In-line
Jan-02-18 Initiated Evercore ISI Outperform
Jan-02-18 Initiated Goldman Neutral
Jan-02-18 Initiated JP Morgan Overweight
Jan-02-18 Initiated Morgan Stanley Overweight
View All

Denali Therapeutics Inc Stock (DNLI) Latest News

pulisher
04:27 AM

Denali Therapeutics (NASDAQ:DNLI) Trading Up 6.4%Still a Buy? - MarketBeat

04:27 AM
pulisher
11:06 AM

Sanofi, Denali face trial setback for neuro drug (NASDAQ:DNLI) - Seeking Alpha

11:06 AM
pulisher
11:00 AM

Denali Therapeutics (NASDAQ:DNLI) Price Target Lowered to $28.00 at JPMorgan Chase & Co. - MarketBeat

11:00 AM
pulisher
07:50 AM

Denali Therapeutics Inc [DNLI] Director makes an insider purchase of 30,000 shares worth 0.87 million. - Knox Daily

07:50 AM
pulisher
07:49 AM

Denali Therapeutics Inc (DNLI)’s stock price in review: A technical analysis - US Post News

07:49 AM
pulisher
Oct 10, 2024

8 Stocks Jeff Bezos is Buying - Insider Monkey

Oct 10, 2024
pulisher
Oct 10, 2024

Denali-Sanofi scraps mid-stage study for multiple sclerosis drug - Reuters

Oct 10, 2024
pulisher
Oct 10, 2024

Denali Therapeutics halts multiple sclerosis study By Investing.com - Investing.com UK

Oct 10, 2024
pulisher
Oct 10, 2024

Denali Therapeutics' (DNLI) "Market Perform" Rating Reiterated at Raymond James - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

How the (DNLI) price action is used to our Advantage - Stock Traders Daily

Oct 10, 2024
pulisher
Oct 08, 2024

Analyzing the Impact of Earnings Reports on Denali Therapeutics Inc Inc. (DNLI) Price Performance - The InvestChronicle

Oct 08, 2024
pulisher
Oct 08, 2024

The Potential Rise in the Price of Denali Therapeutics Inc (DNLI) following insiders activity - Knox Daily

Oct 08, 2024
pulisher
Oct 08, 2024

Denali Therapeutics Inc’s Market Journey: Closing Weak at 26.60, Down -7.09 - The Dwinnex

Oct 08, 2024
pulisher
Oct 08, 2024

The Manufacturers Life Insurance Company Grows Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Oct 08, 2024
pulisher
Oct 07, 2024

Denali Therapeutics (NASDAQ:DNLI) Shares Gap DownTime to Sell? - MarketBeat

Oct 07, 2024
pulisher
Oct 07, 2024

Denali Therapeutics (NASDAQ:DNLI) Rating Lowered to Neutral at Cantor Fitzgerald - MarketBeat

Oct 07, 2024
pulisher
Oct 07, 2024

Algert Global LLC Lowers Stake in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Oct 07, 2024
pulisher
Oct 03, 2024

Squarepoint Ops LLC Has $2.87 Million Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Oct 03, 2024
pulisher
Oct 02, 2024

Steve E. Krognes Sells 30,000 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock - MarketBeat

Oct 02, 2024
pulisher
Oct 02, 2024

In the Green: Denali Therapeutics Inc (DNLI) Closes at 28.67, Up/Down -1.58 from Previous Day - The Dwinnex

Oct 02, 2024
pulisher
Oct 02, 2024

Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Holdings Lifted by Dimensional Fund Advisors LP - MarketBeat

Oct 02, 2024
pulisher
Oct 02, 2024

Brokerages Set Denali Therapeutics Inc. (NASDAQ:DNLI) Target Price at $38.33 - MarketBeat

Oct 02, 2024
pulisher
Sep 30, 2024

Thrivent Financial for Lutherans Grows Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Sep 30, 2024
pulisher
Sep 28, 2024

27,014 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Fred Alger Management LLC - MarketBeat

Sep 28, 2024
pulisher
Sep 27, 2024

Point72 Asset Management L.P. Takes $24.45 Million Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Sep 27, 2024
pulisher
Sep 26, 2024

Marshall Wace LLP Boosts Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

Profund Advisors LLC Sells 39,101 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

Ensign Peak Advisors Inc Sells 298,541 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

Denison Mines stock upgraded by BMO analyst citing attractive P/NPV ratio and strong balance sheet - Investing.com India

Sep 25, 2024
pulisher
Sep 24, 2024

Danimer Scientific awarded $1.36 million by DoD - Investing.com India

Sep 24, 2024
pulisher
Sep 24, 2024

Denison Mines Corp. - Baystreet.ca

Sep 24, 2024
pulisher
Sep 24, 2024

This trade activity should not be overlooked: Denali Therapeutics Inc (DNLI) - SETE News

Sep 24, 2024
pulisher
Sep 23, 2024

Denison Mines (NYSEAMERICAN:DNN) Trading Up 5% - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Hood River Capital Management LLC Has $50.28 Million Stock Holdings in Denison Mines Corp. (NYSEAMERICAN:DNN) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Integral Health Asset Management LLC Acquires New Stake in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Danimer Scientific Inc (DNMR Stock: A Sea of Opportunity - The InvestChronicle

Sep 23, 2024
pulisher
Sep 22, 2024

Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased by American Century Companies Inc. - MarketBeat

Sep 22, 2024
pulisher
Sep 20, 2024

State of New Jersey Common Pension Fund D Trims Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Sep 20, 2024
pulisher
Sep 19, 2024

Danimer Scientific, Inc. (NYSE:DNMR) Short Interest Down 5.1% in August - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - Kilgore News Herald

Sep 18, 2024
pulisher
Sep 18, 2024

(DNLI) On The My Stocks Page - Stock Traders Daily

Sep 18, 2024
pulisher
Sep 17, 2024

Denali Therapeutics (NASDAQ:DNLI) Sets New 52-Week High at $31.00 - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

Denali Therapeutics director sells $30,600 in company stock - Investing.com India

Sep 17, 2024
pulisher
Sep 16, 2024

Denali Therapeutics director sells $30,600 in company stock By Investing.com - Investing.com Canada

Sep 16, 2024
pulisher
Sep 16, 2024

Denali Therapeutics director sells $30,600 in company stock - Investing.com

Sep 16, 2024
pulisher
Sep 16, 2024

Denali Therapeutics director sells $30,600 in company stock By Investing.com - Investing.com UK

Sep 16, 2024
pulisher
Sep 16, 2024

Brokers Issue Forecasts for Denali Therapeutics Inc.'s FY2025 Earnings (NASDAQ:DNLI) - MarketBeat

Sep 16, 2024
pulisher
Sep 16, 2024

Rhumbline Advisers Acquires 22,900 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Sep 16, 2024
pulisher
Sep 16, 2024

Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength? - Yahoo Finance

Sep 16, 2024
pulisher
Sep 13, 2024

ClariVest Asset Management LLC Has $533,000 Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Sep 13, 2024
pulisher
Sep 12, 2024

Denali Therapeutics Insiders Sell US$1.8m Of Stock, Possibly Signalling Caution - Simply Wall St

Sep 12, 2024

Denali Therapeutics Inc Stock (DNLI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.53
price down icon 0.76%
$358.22
price up icon 1.10%
$58.29
price up icon 2.57%
$236.10
price down icon 1.37%
$120.52
price up icon 1.82%
$536.70
price up icon 1.79%
Cap:     |  Volume (24h):